CoChat

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Due to its regulation of CDK1/2 phosphorylation, WEE1 plays essentially roles in the regulations of G2/M checkpoint and DNA damage response (DDR). WEE1 inhibition can increase genomic instability by inducing replication stress and G2/M checkpoint inactivation, which result in increased cellular sensitivity to DNA damaging agents. We considered an increase in genomic instability induced by WEE1 inhibition might be used to augment the effects of drugs targeting DNA repair protein. Typically, PARP inhibitors are effective in germline BRCA 1/2 mutated breast and ovarian cancer, but their applicabilities in triple-negative breast cancer (TNBC) are limited. This study was conducted to investigate the anti-tumor effects of the WEE1 inhibitor, AZD1775, and the mechanism responsible for its potentiation of sensitivity to olaparib (a PARP inhibitor) via the modulation of DDR in TNBC cells. Our results suggest that AZD1775 could be used to broaden the application range of olaparib in TNBC and provide a rationale for a clinical trial of combined olaparib and AZD1775 therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-66018-5

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Anti-proliferative effect of AZD1775 in TNBC cells. (a) The different anti-proliferative effects of AZD1775 in TNBC cells. Growth inhibitions were measured using an MTT assay. Cells were treated with increasing doses of AZD1775 for 5 d. Percentages of surviving cells are presented with ±SE bars (n = 3). (b) p53 protein expression levels in TNBC cells increased with IC50 values. (c) AZD1775 treatment increased sub-G1 populations. Cellular DNA contents were measured by flow cytometry after PI staining. Sub-G1 proportions are shown in the bar graph. Bars represent ±SDs (n = 3). ***P < 0.001. (d) AZD1775 induced apoptosis in MDA-MB-231 cells. MDA-MB-231 and MDA-MB-468 cells were treated with AZD1775 at 350 nmol/L for 5 d, and annexin-V PI staining was performed to identify apoptotic cells. Bars represent ±SDs (n = 3). ***P < 0.001. (e) Caspase-dependent apoptosis induced by AZD1775. After 5 d of treatment with AZD1775 350 nmol/L, MDA-MB-231, and MDA-MB-468 cells were analyzed by Western blotting and probed with anti-PARP, caspase-3, and α-tubulin antibody. We used several gels to examine protein expression. But the results were all derived the same experiment, and the gels and blots were processed in parallel.
Figure 1 Anti-proliferative effect of AZD1775 in TNBC cells. (a) The different anti-proliferative effects of AZD1775 in TNBC cells. Growth inhibitions were measured using an MTT assay. Cells were treated with increasing doses of AZD1775 for 5 d. Percentages of surviving cells are presented with ±SE bars (n = 3). (b) p53 protein expression levels in TNBC cells increased with IC50 values. (c) AZD1775 treatment increased sub-G1 populations. Cellular DNA contents were measured by flow cytometry after PI staining. Sub-G1 proportions are shown in the bar graph. Bars represent ±SDs (n = 3). ***P < 0.001. (d) AZD1775 induced apoptosis in MDA-MB-231 cells. MDA-MB-231 and MDA-MB-468 cells were treated with AZD1775 at 350 nmol/L for 5 d, and annexin-V PI staining was performed to identify apoptotic cells. Bars represent ±SDs (n = 3). ***P < 0.001. (e) Caspase-dependent apoptosis induced by AZD1775. After 5 d of treatment with AZD1775 350 nmol/L, MDA-MB-231, and MDA-MB-468 cells were analyzed by Western blotting and probed with anti-PARP, caspase-3, and α-tubulin antibody. We used several gels to examine protein expression. But the results were all derived the same experiment, and the gels and blots were processed in parallel.CC BY · PubMed Central
Figure 2 AZD1775 accelerated S phase progression and mitotic entry. (a) AZD1775 induced S phase accumulation in the MDA-MB-231 and BT-549 cell lines. TNBC cells were treated with AZD1775 at 350 nmol/L for 5 d, and cellular DNA contents were measured by flow cytometry after PI staining. The proportions of cells in each stage of the cell cycle are shown in the bar graph. Bars represent ±SDs (n = 3). **P < 0.01, ***P < 0.001. (b) AZD1775 accelerated S phase progression in MDA-MB-231 cells. Following treatment with 350 nmol/L AZD1775 for 24 h, S phase progression was examined by EdU-BrdU dual pulse labeling. EdU/BrdU(−/+) indicates the early S phase, and EdU/BrdU(+/+) indicates the mid/late S phase. At least 10000 cells were counted per group in an experiment. Data were collected from 3 independent experiments. Bars represent ±SDs. *P < 0.05. (c) Early mitotic entry induced by WEE1 inhibition in the MDA-MB-231 cell line. After treatment under the above conditions, p-HH3 (orange colored) antibody was applied to TNBC cells that had incorporated EdU (green colored) to investigate mitotic phase cells in S phase cells. At least 10000 cells were counted per group in an experiment. Data were collected from 3 independent experiments. Bars represent ±SDs. ***P < 0.001. (d) AZD1775 increased the proportion of cells with a DNA content of more than 4n. TNBC cells were treated with 350 nmol/L AZD1775 for 5 d and PI-stained. Cells with high DNA contents were identified by flow cytometry. Bars represent ±SDs (n = 3). *P < 0.05, **P < 0.01. (e) The proportion of multinucleated MDA-MB-231 cells increased in response to AZD1775. The nuclei of MDA-MB-231 and MDA-MB-468 cells were stained with DAPI, and the proportions of multinucleated cells were determined by confocal microscopy. White arrows indicate multinucleated nuclei. MDA-MB-231 and MDA-MB-468 cells were treated with 200 nmol/L AZD1775 for 5 d. A total of 100 cells per group were analyzed. Bars represent ±SDs (n = 3). **P < 0.01.
Figure 2 AZD1775 accelerated S phase progression and mitotic entry. (a) AZD1775 induced S phase accumulation in the MDA-MB-231 and BT-549 cell lines. TNBC cells were treated with AZD1775 at 350 nmol/L for 5 d, and cellular DNA contents were measured by flow cytometry after PI staining. The proportions of cells in each stage of the cell cycle are shown in the bar graph. Bars represent ±SDs (n = 3). **P < 0.01, ***P < 0.001. (b) AZD1775 accelerated S phase progression in MDA-MB-231 cells. Following treatment with 350 nmol/L AZD1775 for 24 h, S phase progression was examined by EdU-BrdU dual pulse labeling. EdU/BrdU(−/+) indicates the early S phase, and EdU/BrdU(+/+) indicates the mid/late S phase. At least 10000 cells were counted per group in an experiment. Data were collected from 3 independent experiments. Bars represent ±SDs. *P < 0.05. (c) Early mitotic entry induced by WEE1 inhibition in the MDA-MB-231 cell line. After treatment under the above conditions, p-HH3 (orange colored) antibody was applied to TNBC cells that had incorporated EdU (green colored) to investigate mitotic phase cells in S phase cells. At least 10000 cells were counted per group in an experiment. Data were collected from 3 independent experiments. Bars represent ±SDs. ***P < 0.001. (d) AZD1775 increased the proportion of cells with a DNA content of more than 4n. TNBC cells were treated with 350 nmol/L AZD1775 for 5 d and PI-stained. Cells with high DNA contents were identified by flow cytometry. Bars represent ±SDs (n = 3). *P < 0.05, **P < 0.01. (e) The proportion of multinucleated MDA-MB-231 cells increased in response to AZD1775. The nuclei of MDA-MB-231 and MDA-MB-468 cells were stained with DAPI, and the proportions of multinucleated cells were determined by confocal microscopy. White arrows indicate multinucleated nuclei. MDA-MB-231 and MDA-MB-468 cells were treated with 200 nmol/L AZD1775 for 5 d. A total of 100 cells per group were analyzed. Bars represent ±SDs (n = 3). **P < 0.01.CC BY · PubMed Central
Figure 3 WEE1 inhibition resulted in HR impairment. (a) The expression levels of DNA damage response proteins were assessed by western blotting after treatment of AZD1775 350 nmol/L with MDA-MB-231, BT-549 and MDA-MB-468 for 48 h. (b) AZD1775 caused DNA damage accumulation. Cells were treated with 350 nmol/L AZD1775 for 5 d and DNA double-strand breaks in cells were assessed using a comet assay. Data presented are the mean tail length ±SD from a single representative experiment (n = 3). The scale bar indicates 200 µm. *P < 0.05, **P < 0.01. (c) AZD1775 inhibited the formation of RAD51 foci at sites of DNA damage. After treatment with 350 nmol/L of AZD1775 for 48 h, numbers of RAD51 (red) and γ-H2AX (green) foci in cells were determined by immunoblotting and confocal microscopy. A total of 100 cells per group were analyzed, and cells with at least 5 foci were regarded as positive. DNA was counterstained with DAPI (blue). The scale bar indicates 10 µm. Bars represent ±SDs (n = 3). **P < 0.01. We used several gels to examine protein expression. But the results were all derived the same experiment, and the gels and blots were processed in parallel.
Figure 3 WEE1 inhibition resulted in HR impairment. (a) The expression levels of DNA damage response proteins were assessed by western blotting after treatment of AZD1775 350 nmol/L with MDA-MB-231, BT-549 and MDA-MB-468 for 48 h. (b) AZD1775 caused DNA damage accumulation. Cells were treated with 350 nmol/L AZD1775 for 5 d and DNA double-strand breaks in cells were assessed using a comet assay. Data presented are the mean tail length ±SD from a single representative experiment (n = 3). The scale bar indicates 200 µm. *P < 0.05, **P < 0.01. (c) AZD1775 inhibited the formation of RAD51 foci at sites of DNA damage. After treatment with 350 nmol/L of AZD1775 for 48 h, numbers of RAD51 (red) and γ-H2AX (green) foci in cells were determined by immunoblotting and confocal microscopy. A total of 100 cells per group were analyzed, and cells with at least 5 foci were regarded as positive. DNA was counterstained with DAPI (blue). The scale bar indicates 10 µm. Bars represent ±SDs (n = 3). **P < 0.01. We used several gels to examine protein expression. But the results were all derived the same experiment, and the gels and blots were processed in parallel.CC BY · PubMed Central
Figure 4 Co-administration of olaparib and AZD1775 had a synergistic, anti-proliferative effect on TNBC cells. (a) Sub-G1 population after co-treatment. MDA-MB-231 and Hs 578 T cells were treated with AD1775 at 250 nmol/L and/or olaparib at 2.5 μmol/L for 5 d, sub-G1 populations were investigated by flow cytometry. Bars represent ±SDs (n = 3). ***P < 0.001. (b) Increased sensitivity to olaparib by AZD1775. Cellular DNA contents were measured by flow cytometry after PI staining. Sub-G1 proportions are shown in the bar graph. Bars represent ±SDs (n = 3). ***P < 0.001. (c) Co-treatment with AZD1775 and olaparib increased damaged DNA accumulation as compared with treatment with either agent alone. MDA-MB-231 and Hs 578 T cells were treated with AD1775 at 250 nmol/L and/or olaparib at 2.5 μmol/L for 5 d. The scale bars indicate 200 μm. Data presented are the mean tail length ±SD from a single representative experiment. *P < 0.05, **P < 0.01. (one-way ANOVA: Duncan’s post-hoc Test). (d) AZD1775 inhibited the formation of RAD51 foci caused by olaparib. Blue indicates DAPI staining, representing DNA, green indicates γ-H2AX, representing the degree of DNA damage, and RAD51, which was used to confirm HR capacity, is indicated by red. The scale bar indicates 20 µm. 100 cells were counted per group in a treatment. Bars represent ±SDs (n = 3).
Figure 4 Co-administration of olaparib and AZD1775 had a synergistic, anti-proliferative effect on TNBC cells. (a) Sub-G1 population after co-treatment. MDA-MB-231 and Hs 578 T cells were treated with AD1775 at 250 nmol/L and/or olaparib at 2.5 μmol/L for 5 d, sub-G1 populations were investigated by flow cytometry. Bars represent ±SDs (n = 3). ***P < 0.001. (b) Increased sensitivity to olaparib by AZD1775. Cellular DNA contents were measured by flow cytometry after PI staining. Sub-G1 proportions are shown in the bar graph. Bars represent ±SDs (n = 3). ***P < 0.001. (c) Co-treatment with AZD1775 and olaparib increased damaged DNA accumulation as compared with treatment with either agent alone. MDA-MB-231 and Hs 578 T cells were treated with AD1775 at 250 nmol/L and/or olaparib at 2.5 μmol/L for 5 d. The scale bars indicate 200 μm. Data presented are the mean tail length ±SD from a single representative experiment. *P < 0.05, **P < 0.01. (one-way ANOVA: Duncan’s post-hoc Test). (d) AZD1775 inhibited the formation of RAD51 foci caused by olaparib. Blue indicates DAPI staining, representing DNA, green indicates γ-H2AX, representing the degree of DNA damage, and RAD51, which was used to confirm HR capacity, is indicated by red. The scale bar indicates 20 µm. 100 cells were counted per group in a treatment. Bars represent ±SDs (n = 3).CC BY · PubMed Central
Figure 5 Co-treatment with AZD1775 and olaparib significantly inhibited tumor growth in our mouse xenograft model of MDA-MB-231 human breast cancer. (a) Treatment with AZD1775 plus olaparib significantly inhibited tumor growth the mouse model. Mice were treated with vehicle alone (n = 4), 60 mg/kg AZD1775 (n = 4), 40 mg/kg olaparib (n = 4), or both drugs (n = 5). Tumor volumes were measured three times weekly and are plotted with SE bars. ***P < 0.001. (b) Changes in mouse weights during the treatment period. Body weights were measured three times weekly. Bars, ± SEs. (c) Histological assessments of tumor response to AZD1775 alone and AZD1775 plus olaparib. The tumors were removed immediately after drug treatment, and pathologic examinations were conducted using hematoxylin and eosin (H&E) stained slides X20. Scale bars represent 50 μm. IHC staining for Ki-67 and a TUNEL assay were used to assess proliferation and apoptosis, respectively. AZD1775 reduced the level of p-CDK1(Tyr15). The scale bars represent 50 μm. Red arrows indicates each Ki-67, TUNEL, and p-CDK1(Tyr15) stained section.
Figure 5 Co-treatment with AZD1775 and olaparib significantly inhibited tumor growth in our mouse xenograft model of MDA-MB-231 human breast cancer. (a) Treatment with AZD1775 plus olaparib significantly inhibited tumor growth the mouse model. Mice were treated with vehicle alone (n = 4), 60 mg/kg AZD1775 (n = 4), 40 mg/kg olaparib (n = 4), or both drugs (n = 5). Tumor volumes were measured three times weekly and are plotted with SE bars. ***P < 0.001. (b) Changes in mouse weights during the treatment period. Body weights were measured three times weekly. Bars, ± SEs. (c) Histological assessments of tumor response to AZD1775 alone and AZD1775 plus olaparib. The tumors were removed immediately after drug treatment, and pathologic examinations were conducted using hematoxylin and eosin (H&E) stained slides X20. Scale bars represent 50 μm. IHC staining for Ki-67 and a TUNEL assay were used to assess proliferation and apoptosis, respectively. AZD1775 reduced the level of p-CDK1(Tyr15). The scale bars represent 50 μm. Red arrows indicates each Ki-67, TUNEL, and p-CDK1(Tyr15) stained section.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 82

Metadata

Authors
Ha, D.-H., Min, A., Kim, S., Jang, H., Kim, S. H., Kim, H.-J., Ryu, H. S., Ku, J.-L., Lee, K.-H., & Im, S.-A.
Affiliations
Seoul National University (KR)
Corresponding author
Im, Seock-Ah
Venue
Scientific Reports
Published
2020-06-18
Volume
10
Issue
1
Pages
9930-9930
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3035950992
Cited by
78
References
41
Citations by year
2026: 8 · 2025: 9 · 2024: 11 · 2023: 15 · 2022: 17 · 2021: 15 · 2020: 3
FWCI
4.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • Korea Health Industry Development Institute (HI14C1277)
  • Seoul National University Hospital (043-2018-0011)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
WEE1 inhibition, AZD1775, olaparib, triple-negative breast cancer, PARP inhibitors, DNA damage response, G2/M checkpoint, genomic instability, replication stress, combination therapy, radiosensitization
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Animals, Cell Cycle, DNA Damage, DNA Repair, Drug Synergism, Enzyme Inhibitors, Female, Humans, Mice, Inbred BALB C, Mice, Nude, Phthalazines, Piperazines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidinones, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Apoptosis, Cell Cycle Proteins, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. https://app.cochat.ai/papers/10.1038/s41598-020-66018-5
The paper
Ha, D.-H., Min, A., Kim, S., Jang, H., Kim, S. H., Kim, H.-J., Ryu, H. S., Ku, J.-L., Lee, K.-H., & Im, S.-A. (2020). Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Scientific Reports. https://doi.org/10.1038/s41598-020-66018-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.